Introduction
Multiple sclerosis (MS) is a central nervous system inflammatory disorder of multifactorial origin. Over the past decades, large efforts have been carried out to identify genetic factors involved in the disease [1] [2] [3] and three genetic factors have been identified to date, human leukocyte antigen (HLA), 4 IL2Ra and IL7R. [5] [6] [7] [8] [9] MS is genetically linked and associated with HLA-DRB1*15 allele 10 (referred to as DR15 in the following) with an increased risk ranging from 2 to 6. 10 MS is usually classified according to its evolution into relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) forms. Progression is defined by the steady and irreversible worsening of symptoms and signs over 6 months. SP MS is consensually defined as an initial relapsing-remitting disease course followed by progression, 11 and the median time to onset of the progressive phase has been estimated to be around 8-12 years. [12] [13] [14] Most of the published studies so far have aimed at finding associations between DNA markers and MS susceptibility and very few studies have attempted to correlate disease clinical features with DNA variants. [14] [15] [16] [17] A possible explanation is that it is usually difficult in practice and very expensive to collect both DNA and high-quality clinical information required for these studies on a large enough collection of patients. In France, through a national network REFGENSEP (Réseau Français d'Etude Génétique de la SEP), we have been able to collect the DNA of a large number of MS patients and their parents (651 case-parent trios). Patients were of Caucasian origin and originated from all over France. All, patients and parents, were ascertained using defined criteria, which have been previously described 18 by a board-certified neurologist. 19 Clinical information was collected according to a written and standardized protocol including at least one clinical examination. Follow-up data were obtained from neurologists if available or through a questionnaire sent to patients. The disease severity was assessed according to the Expanded Disease Status Scale (EDSS) by a neurologist from REFGENSEP. 20 The time from clinical onset to reach EDSS 6.0 (walking with unilateral aid) was documented by a neurologist and rarely by the patient himself. A clinician taking into account potential memory and cognitive deficits checked all the data from the questionnaire documented by the patient himself.
These valuable resources enabled us to address the question of whether or not genetic factors play a role in disease or disability progression. In this paper, we focused on HLA, the best characterized MS genetic factor.
Results and discussion
Clinical features of patients MS onset was defined as relapsing or progressive, and the MS form at the last assessment was classified according to accepted criteria into RR, SP and PP, although relapsing-progressive and progressive forms were not distinguished and pooled in the PP sample.
11
RR and SP patients represent MS patients with relapsing onset.
Among the 651 patients included in the DNA base, 457 (70.3%) were females and 194 (29.7%) males that is, a sex ratio (F/M) of 2.4:1. Mean age at onset, mean follow-up duration after clinical onset and percentage of patients according to MS form are presented in Table 1 . Among the 575 patients with relapsing onset, 464 were still relapsing-remitting at the last assessment and 111 had shifted to the secondary progressive phase. The sex ratio, the age at onset, the course of MS in our sample of patients were similar to features published in observational studies of MS, 12, 14 indicating that our collection fits the required quality and is unbiased by treatments and reflects the natural history of MS (see Table 1 ).
The most appropriate way to evaluate severity in observational studies of MS has been a subject of debate. Recently, Roxburgh et al. 21 introduced the Multiple Sclerosis Severity Score (MSSS) to assess disease disability in patients having a single assessment, such as those participating in genetic studies. It has been also proposed to focus on the median time to reach disability milestones of the EDSS scale. An EDSS score of 6.0 was chosen as the most robust score even when documented by the patient himself, being an important step in the disease course. 14 Mean MSSS are presented in Table 1 for the total sample and according to MS form at onset.
Out of the 651 patients, 601 were included in the calculation of median time to reach EDSS 6.0 from clinical onset. It was 20 years [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] in the total group, 31 years [26] [27] [28] [29] [30] [31] [32] in the RR MS group, 14 years [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] in the SP MS group and 9 years [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] in the PP MS group ( Figure 1 ). As expected, these figures were significantly Figure 1 Median time to reach Expanded Disease Status Scale (EDSS) 6 for all patients and patients stratified according to MS type. RR, relapsing-remitting course; SP, secondary progressive course; PP, primary progressive. Medians were calculated by standard programs and are presented with 25-75 percentile range (Q1-Q3). Whenever the chosen disability score had not been reached at the time of the study, data were censored at the time of the last clinical assessment. Patients who reached EDSS6 at an unknown date were not included in the analysis (n ¼ 50). We used Kaplan-Meier method to estimate survival curves and compared them using log-rank test. All analyses were performed using SigmaStat software (version 3.1).
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Primary progressive patients reached EDSS 6.0 significantly earlier than secondary progressive and RelapsingRemitting patients, which fits with the known natural history of MS.
Correlation of clinical course and HLA status
The involvement of DR15 genotype in MS course and severity is debated. In a recent publication, Hensiek et al. 16 concluded that although genetic factors do not significantly affect disease severity, they increase the probability of a progressive clinical course of MS. Barcellos et al. 22 proposed in 2003 that DR15-positive patients were at greater risk for a more severe disease outcome, whereas no effect was evidenced on disease type. In 2006, the same group analyzed a larger number of MS cases that did not confirm their prior proposal. 23 To gain a deeper insight into the role of DR15 genotype on severity and on disease form than previously done, we studied a population better characterized for severity by using more reliable markers such as the MSSS score and time to reach EDSS 6.0 from disease onset. The mean MSSS scores estimated with the MSSS test program using the global MSSS were 4.7 and 4.6, respectively, for DR15 carriers and non-carriers. They were not significantly different, even after stratification on MS form at onset ( Table 2) . We concluded that DR15 genotype did not influence MS severity as evaluated by MSSS.
Therefore, we stratified our population according to disease forms based on the rationale that the different forms of MS differ in the severity of progression, and used Kaplan-Meier curves to describe time for MS patients to reach an EDSS score of 6.0 from clinical onset according to their HLA status. The number of patients in each group is shown in Table 2 . In the total group, the median time to reach EDSS 6.0 was higher for DR15-negative as compared with DR15-positive patients: 25 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] (Figure 2a ), but the difference was not statistically significant. After stratification on MS form at onset, there was no significant difference in the median time to reach EDSS 6.0 between DR15-positive and DR15-negative patients (Figure 2b ) in the PP group. However, in the relapsing onset group, the median time to reach EDSS 6.0 from clinical onset was significantly higher for DR15-negative patients than for DR15-positive ones (26 versus 20 years, P ¼ 0.026) (Figure 2c ). To evaluate the potential confounding influence of age at onset and gender, we compared Kaplan-Meier curves describing time to reach EDSS score of 6.0 from clinical onset according to age at onset and sex of the patients. We observed that time to reach EDSS score of 6.0 for patients with age at onset greater than 40 years was significantly shorter than for others but among these 38 patients neither the repartition of HLA status nor MS form were heterogeneous (Supplementary Table 1 ). Concerning sex, no statistical difference was observed between male and female (P ¼ 0.431) (Supplementary Figure 1) .
Hypothesizing that these results could suggest a role of DR15 genotype in the conversion into SP MS, we compared the distribution of the DR15 genotype according to the MS form and to the disease duration for RR patients. As shown in Table 3 , an excess of DR15-positive patients was found among SP patients (67/111 ¼ 60%) as compared with RR patients with more than 12 years of disease duration who are low-risk SP patients (49/ 110 ¼ 44%) (w 2 test of homogeneity ¼ 5.54, P ¼ 0.018). These results, even if borderline statistically significant, clearly sustain our proposal.
To ensure that the differences found in MS patients are not due to some hidden population variable, we also used the available familial information and compared the transmissions of DR15 allele from parents to affected offspring in the 645 case-parent trios available. As expected, a very strong association with the DR15 allele was observed (Po3 10 À31 ), the HLA DRB1*14 allele was found to have a protective effect (P ¼ 0.04) and we confirmed a dose effect of HLA DR15 (P ¼ 0.55) (see Supplementary Table 2) .
Transmission of DR15 allele according to MS form at the last assessment is shown in Table 4 . It is noticeable that the transmission rate of DR15 allele is greater for SP patients than for RR or PP patients (0.87 versus 0.76 and 0.77, respectively, for RR and SP). To test if these differences were significant, we could not simply compare the transmission rates in the different disease forms as this test might also be biased by the presence of some hidden variable in the population. We used a log-linear model similar to the one proposed by Umbach et al. 24 to test gene Â environment interaction that compares the genotype distribution of exposed and unexposed cases conditionally on the parental genotypes. The exposure here was whether or not the patient switches in an SP form of the disease. As the number of DR15 homozygous carriers with an SP form was too small we considered the DR15 genotype whether than the allele, assuming a dominant model of DR15 locus. Using this model, an interaction between the disease form and the DR15 genotype was detected (P ¼ 0.027) indicating that the distribution of the DR15 genotype is indeed different depending on the clinical form of the disease. No difference depending on the disease duration was found among RR patients. Abbreviations: MS, multiple sclerosis; PP, primary progressive form; RR, relapsing-remitting form; SP, secondary progressive form.
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In conclusion, we show that our collection of patients is unbiased regarding the natural history of MS and for the first time that HLA-DRB1*15 allele modulates the course of MS likely by precipitating the secondary progressive phase. If we consider that HLA DR15 influences the conversion of RR to SP MS, we may speculate that HLA is not only implicated in the early phase of the disease (susceptibility) but also in the later course of MS. 25 
